CoChat
Sign Up
Cited by 274Diabetes Treatment and ManagementCardiovascular Function and Risk FactorsHeart Failure Treatment and Management

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy

Nikolaidis, Lazaros A., Elahi, Dariush, Shen, You-Tang, Shannon, Richard P.·2005·American Journal of Physiology-Heart and Circulatory Physiology
DOI 10.1152/ajpheart.00347.2005
Open this paper in CoChat — free account

Abstract

We have shown previously that the glucagon-like peptide-1 (GLP-1)-(7–36) amide increases myocardial glucose uptake and improves left ventricular (LV) and systemic hemodynamics in both conscious dogs with pacing-induced dilated cardiomyopathy (DCM) and humans with LV systolic dysfunction after acute myocardial infarction. However, GLP-1-(7–36) is rapidly degraded in the plasma to GLP-1-(9–36) by dipeptidyl peptidase IV (DPP IV), raising the issue of which peptide is the active moiety. By way of methodology, we compared the efficacy of a 48-h continuous intravenous infusion of GLP-1-(7–36) (1.5 pmol·kg−1·min−1) to GLP-1-(9–36) (1.5 pmol·kg−1·min−1) in 28 conscious, chronically instrumented dogs with pacing-induced DCM by measuring LV function and transmyocardial substrate uptake under basal and insulin-stimulated conditions using hyperinsulinemic-euglycemic clamps. As a result, dogs with DCM demonstrated myocardial insulin resistance under basal and insulin-stimulated conditions. Both GLP-1-(7–36) and GLP-1-(9–36) significantly reduced ( P < 0.01) LV end-diastolic pressure [GLP-1-(7–36), 28 ± 1 to 15 ± 2 mmHg; GLP-1-(9–36), 29 ± 2 to 16 ± 1 mmHg] and significantly increased ( P < 0.01) the first derivative of LV pressure [GLP-1-(7–36), 1,315 ± 81 to 2,195 ± 102 mmHg/s; GLP-1-(9–36), 1,336 ± 77 to 2,208 ± 68 mmHg] and cardiac output [GLP-1-(7–36), 1.5 ± 0.1 to 1.9 ± 0.1 l/min; GLP-1-(9–36), 2.0 ± 0.1 to 2.4 ± 0.05 l/min], whereas an equivolume infusion of saline had no effect. Both peptides increased myocardial glucose uptake but without a significant increase in plasma insulin. During the GLP-1-(9–36) infusion, negligible active (NH 2-terminal) peptide was measured in the plasma. In conclusion, in DCM, GLP-1-(9–36) mimics the effects of GLP-1-(7–36) in stimulating myocardial glucose uptake and improving LV and systemic hemodynamics through insulinomimetic as opposed to insulinotropic effects. These data suggest that GLP-1-(9–36) amide is an active peptide.

Overview

Integrity signals

Registry

Crossref · 10.1152/ajpheart.00347.2005

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 27 references

Cited by

Sorted by citations

Items 201–272 of 272

Related

See all

Metadata

Authors
Nikolaidis, L. A., Elahi, D., Shen, Y.-T., & Shannon, R. P.
Affiliations
Allegheny General Hospital (US)
ORCID
Nikolaidis, Lazaros A.
Venue
American Journal of Physiology-Heart and Circulatory Physiology
Publisher
American Physiological Society
Published
2005-12
Volume
289
Issue
6
Pages
H2401-H2408
ISSN
  • 0363-6135 (ISSN-L)
  • 1522-1539
DOI
10.1152/ajpheart.00347.2005
OpenAlex
W2169976140
Cited by
274
References
27
Citations by year
2025: 4 · 2024: 5 · 2023: 4 · 2022: 8 · 2021: 4 · 2020: 5 · 2019: 12 · 2018: 12 · 2017: 8 · 2016: 19 · 2015: 15 · 2014: 29 · 2013: 22 · 2012: 26
FWCI
6.37
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Physiology-Heart and Circulatory Physiology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (7r01da010480-09, 5r01ag023125-05)
  • National Institute on Aging (AG-023125)
  • National Institute on Drug Abuse (DA 10480)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
glucagon-like peptide-1, GLP-1(7-36), dipeptidyl peptidase IV, dilated cardiomyopathy, pacing-induced cardiomyopathy, myocardial glucose uptake, myocardial insulin resistance, left ventricular function, hemodynamics, cardiac output, myocardial substrate metabolism, hyperinsulinemic-euglycemic clamp
MeSH terms
Animals, Blood Pressure, Cardiomyopathy, Dilated, Consciousness, Coronary Circulation, Dogs, Dose-Response Relationship, Drug, Glucagon-Like Peptides, Female, Glucagon, Glucose, Heart, Heart Ventricles, Male, Myocardium, Peptide Fragments, Peptides, Stroke Volume, Treatment Outcome, Ventricular Dysfunction, Left, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review